2-bromo-5-(4-fluorophenyl)pyridine | 868254-43-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-bromo-5-(4-fluorophenyl)pyridine
• CAS: 868254-43-7
• 化学式: C₁₁H₇BrFN
• 分子量: 252.086
• InChiKey: MWZSJTIJQVUACR-UHFFFAOYSA-N

物化性质

• 沸点：
  332.4±27.0 °C(Predicted)
• 密度：
  1.497±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴-5-碘吡啶 、 (对氟苯基)3Bi 在 potassium phosphate 、 palladium diacetate 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以66%的产率得到2-bromo-5-(4-fluorophenyl)pyridine
  参考文献：
  名称：

  Cross-coupling study of iodo/chloropyridines and 2-chloroquinoline with atom-economic triarylbismuth reagents under Pd-catalysis

  摘要：

  This study describes the palladium-catalyzed couplings of iodopyridines, chloropyridines, and chloroquinoline with atom-economic BiAr3 reagents in sub-stoichiometric loadings. Mono-arylations of iodo and chloropyridines produced arylpyridines in high yields. The couplings addressed with dihalopyridines have afforded chemo- and regio-selective coupling products. Arylations of 2-chloroquinoline with different triarylbismuth reagents demonstrated fruitful coupling reactivity under the established conditions. This sumptuous study demonstrates the remarkable cross-coupling reactivity of iodo/chloropyridines and chloroquinoline with triarylbismuth reagents. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.11.036

文献信息

• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2018118838A1

  公开（公告）日：2018-06-28

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与酶神经鞘糖脂转移酶（CGT）相关的疾病或紊乱的方法，例如溶酶体贮积症。溶酶体贮积症的例子包括 Krabbe 病和白质变性白血病。
• Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1741708A1

  公开（公告）日：2007-01-10

  The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的N-烷基酰胺， 其中A、Het、X、R1、R2和R3具有权利要求中所指示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的药物组合物，以及利用公式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Polycyclic pyrazines as potassium ion channel modulators
  申请人：Wang Xiaodong

  公开号：US20050239800A1

  公开（公告）日：2005-10-27

  The present invention provides a genus of polycyclic pyrazines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.

  本发明提供了一类多环吡嗪，可作为钾离子通道调节剂。该发明的调节剂可用于治疗和诊断方法。
• [EN] POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS<br/>[FR] PYRIMIDINES POLYCYCLIQUES UTILISES EN TANT QUE MODULATEURS DU CANAL IONIQUE DU POTASSIUM
  申请人：ICAGEN INC

  公开号：WO2005099711A1

  公开（公告）日：2005-10-27

  The present invention provides a genus of polycyclic pyrimidines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.

  本发明提供了一类多环嘧啶，可作为钾离子通道的调节剂。该发明的调节剂在治疗和诊断方法中均有用处。
• C−I-Selective Cross-Coupling Enabled by a Cationic Palladium Trimer
  作者：Claudia J. Diehl、Thomas Scattolin、Ulli Englert、Franziska Schoenebeck

  DOI：10.1002/anie.201811380

  日期：2019.1.2

  air‐stable Pd trimer and presents unambiguous reactivity data of its privileged capability to differentiate C−I over C−Br bonds in C−C bond formations (arylation and alkylation) of polyhalogenated arenes, which typical Pd0 and PdI‐PdI catalysts fail to deliver. Experimental and computational reactivity data, including the first location of a transition state for bond activation by the trimer, are presented

  尽管人们越来越关注在催化中利用一种以上金属的协同效应，但除双金属体系外，人们所知甚少。该报告描述了直接进入空气稳定的Pd三聚体的方法，并提供了明确的反应性数据，该数据具有在多卤代芳烃的C-C键形成（芳构化和烷基化）中区分C-1与C-Br键的特权。0和Pd I -Pd I催化剂无法输送。给出了实验和计算反应性数据，包括三聚体激活键的过渡态的第​​一个位置，支持直接的三聚体反应性是可行的。